Hepatology
Signal score, how each part rates
ActionabilityPrevalenceStakesEvidence strengthNovelty
See the full rubric →Treatment Goals for Primary Biliary Cholangitis, an Australian Perspective.
Clinical takeawayFor PBC patients on UDCA, assess ALP at 1 year; if ALP ≥1.67x ULN (or bilirubin 1-2x ULN) in Australia, escalate to second-line therapy including PPAR agonists, fenofibrate, or obeticholic acid (subject to precautions). Also escalate if inadequate biochemical response or bothersome symptoms. At diagnosis, identify high-risk patients (male, age <45, ALP >1.5x ULN, anti-gp210 positive, or significant fibrosis) for closer monitoring and earlier therapy consideration.
What it foundAbout 40% of PBC patients have inadequate UDCA response; established progression risk factors are male gender, age <45 years, ALP >1.5x ULN, anti-gp210 antibodies, and significant fibrosis; in Australia, second-line therapy is reimbursed when ALP ≥1.67x ULN or bilirubin 1-2x ULN after 1 year of UDCA.
ContextThis review consolidates established PBC management (UDCA for transplant-free survival) with evolving emphasis on ALP normalization as an aspirational treatment target. Risk stratification and Australian-specific reimbursement thresholds provide practical guidance for clinicians managing PBC in that setting.
Refinessuggested applicable standard· American Association for the Study of Liver Diseases, 'Primary Biliary Cholangitis: 2021 Practice Guidance', 2021
Decision at stakeSet the biochemical response target for UDCA efficacy assessment at 12 months
American Association for the Study of Liver Diseases, 'Primary Biliary Cholangitis: 2021 Practice Guidance', 2021 · reviewed 2026-07-21 ↗Treat with first-line ursodeoxycholic acid (UDCA) 13-15 mg/kg/d divided, and assess biochemical response at 12 months using Paris-II plus continuous risk scores (Globe, UK-PBC). Escalate to a second-line agent (obeticholic acid [contraindicated in cirrhosis with portal hypertension or prior decompensation], seladelpar, elafibranor, or a fibrate) when response is inadequate, guided by a Child-Pugh/portal-hypertension hard gate, and manage pruritus with a stepwise ladder (cholestyramine → rifampin → sertraline → naltrexone). Refer for transplant evaluation for decompensation, refractory pruritus, or rising bilirubin.
Strasser SI … Weltman M · Journal of Gastroenterology and Hepatology · IF 3.5 · PubMed ↗